Cargando…

Immunohistochemistry scoring of breast tumor tissue microarrays: A comparison study across three software applications

Digital pathology can efficiently assess immunohistochemistry (IHC) data on tissue microarrays (TMAs). Yet, it remains important to evaluate the comparability of the data acquired by different software applications and validate it against pathologist manual interpretation. In this study, we compared...

Descripción completa

Detalles Bibliográficos
Autores principales: Baker, Gabrielle M., Bret-Mounet, Vanessa C., Wang, Tengteng, Veta, Mitko, Zheng, Hanqiao, Collins, Laura C., Eliassen, A. Heather, Tamimi, Rulla M., Heng, Yujing J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577037/
https://www.ncbi.nlm.nih.gov/pubmed/36268097
http://dx.doi.org/10.1016/j.jpi.2022.100118
_version_ 1784811666799591424
author Baker, Gabrielle M.
Bret-Mounet, Vanessa C.
Wang, Tengteng
Veta, Mitko
Zheng, Hanqiao
Collins, Laura C.
Eliassen, A. Heather
Tamimi, Rulla M.
Heng, Yujing J.
author_facet Baker, Gabrielle M.
Bret-Mounet, Vanessa C.
Wang, Tengteng
Veta, Mitko
Zheng, Hanqiao
Collins, Laura C.
Eliassen, A. Heather
Tamimi, Rulla M.
Heng, Yujing J.
author_sort Baker, Gabrielle M.
collection PubMed
description Digital pathology can efficiently assess immunohistochemistry (IHC) data on tissue microarrays (TMAs). Yet, it remains important to evaluate the comparability of the data acquired by different software applications and validate it against pathologist manual interpretation. In this study, we compared the IHC quantification of 5 clinical breast cancer biomarkers—estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor (EGFR), and cytokeratin 5/6 (CK5/6)—across 3 software applications (Definiens Tissue Studio, inForm, and QuPath) and benchmarked the results to pathologist manual scores. IHC expression for each marker was evaluated across 4 TMAs consisting of 935 breast tumor tissue cores from 367 women within the Nurses’ Health Studies; each women contributing three 0.6-mm cores. The correlation and agreement between manual and software-derived results were primarily assessed using Spearman’s ρ, percentage agreement, and area under the curve (AUC). At the TMA core-level, the correlations between manual and software-derived scores were the highest for HER2 (ρ ranging from 0.75 to 0.79), followed by ER (0.69–0.71), PR (0.67–0.72), CK5/6 (0.43–0.47), and EGFR (0.38–0.45). At the case-level, there were good correlations between manual and software-derived scores for all 5 markers (ρ ranging from 0.43 to 0.82), where QuPath had the highest correlations. Software-derived scores were highly comparable to each other (ρ ranging from 0.80 to 0.99). The average percentage agreements between manual and software-derived scores were excellent for ER (90.8%–94.5%) and PR (78.2%–85.2%), moderate for HER2 (65.4%–77.0%), highly variable for EGFR (48.2%–82.8%), and poor for CK5/6 (22.4%–45.0%). All AUCs across markers and software applications were ≥0.83. The 3 software applications were highly comparable to each other and to manual scores in quantifying these 5 markers. QuPath consistently produced the best performance, indicating this open-source software is an excellent alternative for future use.
format Online
Article
Text
id pubmed-9577037
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-95770372022-10-19 Immunohistochemistry scoring of breast tumor tissue microarrays: A comparison study across three software applications Baker, Gabrielle M. Bret-Mounet, Vanessa C. Wang, Tengteng Veta, Mitko Zheng, Hanqiao Collins, Laura C. Eliassen, A. Heather Tamimi, Rulla M. Heng, Yujing J. J Pathol Inform Original Research Article Digital pathology can efficiently assess immunohistochemistry (IHC) data on tissue microarrays (TMAs). Yet, it remains important to evaluate the comparability of the data acquired by different software applications and validate it against pathologist manual interpretation. In this study, we compared the IHC quantification of 5 clinical breast cancer biomarkers—estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor (EGFR), and cytokeratin 5/6 (CK5/6)—across 3 software applications (Definiens Tissue Studio, inForm, and QuPath) and benchmarked the results to pathologist manual scores. IHC expression for each marker was evaluated across 4 TMAs consisting of 935 breast tumor tissue cores from 367 women within the Nurses’ Health Studies; each women contributing three 0.6-mm cores. The correlation and agreement between manual and software-derived results were primarily assessed using Spearman’s ρ, percentage agreement, and area under the curve (AUC). At the TMA core-level, the correlations between manual and software-derived scores were the highest for HER2 (ρ ranging from 0.75 to 0.79), followed by ER (0.69–0.71), PR (0.67–0.72), CK5/6 (0.43–0.47), and EGFR (0.38–0.45). At the case-level, there were good correlations between manual and software-derived scores for all 5 markers (ρ ranging from 0.43 to 0.82), where QuPath had the highest correlations. Software-derived scores were highly comparable to each other (ρ ranging from 0.80 to 0.99). The average percentage agreements between manual and software-derived scores were excellent for ER (90.8%–94.5%) and PR (78.2%–85.2%), moderate for HER2 (65.4%–77.0%), highly variable for EGFR (48.2%–82.8%), and poor for CK5/6 (22.4%–45.0%). All AUCs across markers and software applications were ≥0.83. The 3 software applications were highly comparable to each other and to manual scores in quantifying these 5 markers. QuPath consistently produced the best performance, indicating this open-source software is an excellent alternative for future use. Elsevier 2022-06-28 /pmc/articles/PMC9577037/ /pubmed/36268097 http://dx.doi.org/10.1016/j.jpi.2022.100118 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Research Article
Baker, Gabrielle M.
Bret-Mounet, Vanessa C.
Wang, Tengteng
Veta, Mitko
Zheng, Hanqiao
Collins, Laura C.
Eliassen, A. Heather
Tamimi, Rulla M.
Heng, Yujing J.
Immunohistochemistry scoring of breast tumor tissue microarrays: A comparison study across three software applications
title Immunohistochemistry scoring of breast tumor tissue microarrays: A comparison study across three software applications
title_full Immunohistochemistry scoring of breast tumor tissue microarrays: A comparison study across three software applications
title_fullStr Immunohistochemistry scoring of breast tumor tissue microarrays: A comparison study across three software applications
title_full_unstemmed Immunohistochemistry scoring of breast tumor tissue microarrays: A comparison study across three software applications
title_short Immunohistochemistry scoring of breast tumor tissue microarrays: A comparison study across three software applications
title_sort immunohistochemistry scoring of breast tumor tissue microarrays: a comparison study across three software applications
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577037/
https://www.ncbi.nlm.nih.gov/pubmed/36268097
http://dx.doi.org/10.1016/j.jpi.2022.100118
work_keys_str_mv AT bakergabriellem immunohistochemistryscoringofbreasttumortissuemicroarraysacomparisonstudyacrossthreesoftwareapplications
AT bretmounetvanessac immunohistochemistryscoringofbreasttumortissuemicroarraysacomparisonstudyacrossthreesoftwareapplications
AT wangtengteng immunohistochemistryscoringofbreasttumortissuemicroarraysacomparisonstudyacrossthreesoftwareapplications
AT vetamitko immunohistochemistryscoringofbreasttumortissuemicroarraysacomparisonstudyacrossthreesoftwareapplications
AT zhenghanqiao immunohistochemistryscoringofbreasttumortissuemicroarraysacomparisonstudyacrossthreesoftwareapplications
AT collinslaurac immunohistochemistryscoringofbreasttumortissuemicroarraysacomparisonstudyacrossthreesoftwareapplications
AT eliassenaheather immunohistochemistryscoringofbreasttumortissuemicroarraysacomparisonstudyacrossthreesoftwareapplications
AT tamimirullam immunohistochemistryscoringofbreasttumortissuemicroarraysacomparisonstudyacrossthreesoftwareapplications
AT hengyujingj immunohistochemistryscoringofbreasttumortissuemicroarraysacomparisonstudyacrossthreesoftwareapplications